Latest Biotechnology News

Percheron Therapeutics has terminated its phase IIb avicursen trial for Duchenne muscular dystrophy after failing to meet efficacy endpoints, while securing $14.85 million in fresh capital to explore new therapeutic opportunities.

Telix Pharmaceuticals has completed a strategic acquisition of ImaginAb, gaining next-generation therapeutic assets and a novel biologics platform to expand its oncology pipeline and R&D capabilities.

Immutep Limited has initiated its pivotal Phase III trial for eftilagimod alfa in first-line non-small cell lung cancer, supported by compelling survival outcomes from ongoing studies and a robust cash position expected to fund operations through 2026.

Paradigm Biopharmaceuticals has appointed Advanced Clinical as the Clinical Research Organisation for its critical Phase 3 trial targeting knee osteoarthritis pain, setting the stage for patient recruitment and dosing in Q2 2025.

Neurotech International has secured a $2.44 million R&D tax incentive refund, strengthening its cash position as it advances clinical trials for paediatric neurological disorders and prepares for regulatory submissions in FY2025.

Avecho Biotechnology progresses its Phase III clinical trial for a TPM®-enhanced CBD insomnia capsule, expands patient recruitment, and completes a major manufacturing campaign for its U.S. partner Ashland.

Paradigm Biopharmaceuticals has secured FDA clearance for its phase 3 knee osteoarthritis trial and raised $16 million to fund its next clinical steps, positioning the company for a pivotal year ahead.

Bluechiip Limited reported a $221,000 net cash outflow for Q2 FY2025, with cash reserves dwindling to $121,000. The company has initiated a strategic review and plans a capital raise to secure its future.

Zelira Therapeutics has secured a fourth funding tranche of US$681,000, advancing its HOPE® Autism Spectrum Disorder FDA trial process and bringing total funding to US$3.25 million. The company is progressing clinical validation and product development, including the transformation of Zenivol® into a capsule formulation.

ASF Group Limited reported a $1.58 million cash balance for the December 2024 quarter, highlighting ongoing investments and a director retirement that could influence its strategic direction.

Amplia Therapeutics reports encouraging progress in its Phase 2a ACCENT trial for pancreatic cancer, with nine confirmed partial responses and ongoing patient recruitment. The company also strengthens its financial position with a $13 million capital raise to support further clinical development.

Argenica Therapeutics has dosed 80% of patients in its Phase 2 stroke trial and gained FDA orphan drug designations for its second candidate, ARG-006. The company reports a cash-positive quarter with $15 million in reserves.